GlaxoSmithKline plc / Adaptimmune Therapeutics plc

Synovial Sarcoma (NY-ESO-1+ soft tissue sarcoma)

900 US cases/yr

Disease Overview

Synovial sarcoma is an aggressive soft-tissue sarcoma driven by an SS18-SSX gene fusion, accounting for 5–10% of soft-tissue sarcomas and most often diagnosed in adolescents and young adults. Roughly 800–1,000 new US cases per year; ~70% express the cancer-testis antigen NY-ESO-1, making it a tractable TCR cell-therapy target.

Competitive Landscape

Synovial sarcoma is a rare, aggressive soft-tissue sarcoma with ~800–1,000 new US cases annually and a janus-faced therapeutic landscape: standard care relies on surgery, ifosfamide-based chemotherapy and pazopanib (Votrient) — none curative in metastatic disease. Cell therapy targeting NY-ESO-1, expressed in ~70% of synovial sarcomas, has emerged as the differentiated path. Adaptimmune's affinity-enhanced SPEAR T-cell letetresgene autoleucel (lete-cel, GSK3377794) generated a ~50% overall response rate and ~28-month median OS in early Cohort 1 patients, data which underpinned GSK's expanded 2016 collaboration and 2017 option exercise. The 2014 GSK–Adaptimmune deal — undisclosed upfront plus up to $350M+ in milestones across up to five SPEAR programs led by NY-ESO-1 — was the first major Big Pharma validation of engineered TCR therapy and the foundation of the lete-cel program. Competition has since intensified with Adaptimmune's own MAGE-A4 SPEAR therapy afamitresgene autoleucel (Tecelra), FDA-approved August 2024 as the first engineered TCR therapy in synovial sarcoma. GSK transferred the NY-ESO and PRAME programs back to Adaptimmune in 2022, effectively winding down the original deal.